Perifosine inhibits growth of human experimental endometrial cancers by blockade of AKT phosphorylation

Jörg B Engel, Arnd Honig, Tanja Schönhals, Claudia Weidler, Sebastian Häusler, Mathias Krockenberger, Thomas G Grunewald, Yvonne Dombrowski, Lorenz Rieger, Johannes Dietl, Jörg Wischhusen

Research output: Contribution to journalArticlepeer-review

25 Citations (Scopus)

Abstract

Perifosine is an orally active alkylphospholipid analog, which has shown anti-tumor activity in a variety of cancers by inhibition of AKT phosphorylation. The objective of the current study was to evaluate its efficacy in in vitro models of human endometrial cancer.
Original languageEnglish
Pages (from-to)64-9
Number of pages6
JournalEuropean journal of obstetrics, gynecology, and reproductive biology
Volume141
Issue number1
DOIs
Publication statusPublished - Nov 2008

Keywords

  • Antineoplastic Agents
  • Antineoplastic Combined Chemotherapy Protocols
  • Apoptosis
  • Cell Line, Tumor
  • Cisplatin
  • Endometrial Neoplasms
  • Female
  • Humans
  • Phosphorylation
  • Phosphorylcholine
  • Proto-Oncogene Proteins c-akt

Fingerprint Dive into the research topics of 'Perifosine inhibits growth of human experimental endometrial cancers by blockade of AKT phosphorylation'. Together they form a unique fingerprint.

Cite this